Xiaojie Lu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xiaojie Lu has a total of 340 co-authors. Here are the top co-authors by number of shared publications:
Weiwei Lu
State Key Laboratory of Drug Research
28 shared publications- Xuan Wang
Alphama Biotechnology Suzhou Co., Ltd
21 shared publications Jiaxiang Liu
State Key Laboratory of Drug Research
14 shared publicationsXinyuan Wu
State Key Laboratory of Drug Research
13 shared publicationsXuan Wang
State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica
13 shared publicationsYanrui Suo
State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica
13 shared publications
Latest Publications
- 1 August 2026
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
Recent Advances and Future Directions in On-DNA Reaction Development
DNA-encoded library (DEL) technology has emerged as a powerful platform for small-molecule discovery, in which on-DNA reaction development plays a central role in determining accessible chemical space. Early on-DNA chemistry mainly focused on establishing robust DNA-compatible transformations under mild aqueous conditions but often generated structurally limited libraries. Recent advances in photochemistry, electrochemistry, biocatalysis, and complexity-generating reactions have substantially expanded the scope of accessible on-DNA transformations and enabled the incorporation of increasingly diverse and medicinally relevant scaffolds into DELs. In this Viewpoint, we discuss the recent progress and emerging trends in on-DNA reaction development, with particular emphasis on the transition from compatibility-driven chemistry toward function-oriented DEL synthesis. We further highlight current challenges and future opportunities for developing precision on-DNA chemistry to support next-generation ligand discovery.
- 1 August 2026
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
Recent Advances and Future Directions in On-DNA Reaction Development
DNA-encoded library (DEL) technology has emerged as a powerful platform for small-molecule discovery, in which on-DNA reaction development plays a central role in determining accessible chemical space. Early on-DNA chemistry mainly focused on establishing robust DNA-compatible transformations under mild aqueous conditions but often generated structurally limited libraries. Recent advances in photochemistry, electrochemistry, biocatalysis, and complexity-generating reactions have substantially expanded the scope of accessible on-DNA transformations and enabled the incorporation of increasingly diverse and medicinally relevant scaffolds into DELs. In this Viewpoint, we discuss the recent progress and emerging trends in on-DNA reaction development, with particular emphasis on the transition from compatibility-driven chemistry toward function-oriented DEL synthesis. We further highlight current challenges and future opportunities for developing precision on-DNA chemistry to support next-generation ligand discovery.
- 12 June 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (12) , 14530-14554
Discovery of a Covalent Inhibitor Targeting the PHGDH Dimer Interface with Antitumor Efficacy
Protein oligomerization is functionally essential for many enzymes, yet small-molecule strategies that directly target dimer interfaces remain challenging. Cysteine residues at protein dimer interfaces offer chemically addressable sites for modulating oligomeric assembly. Here, we used covalent DNA-encoded chemical library (CoDEL) screening to identify site-selective covalent hits targeting the PHGDH dimer interface. Covalent hits emerging from CoDEL screening were optimized to yield a selective covalent inhibitor engaging the interfacial Cys281. A representative compound, D5-2, potently disrupts PHGDH dimerization and inhibits its enzymatic activity, restores sensitivity to EGFR tyrosine kinase inhibitors in resistant lung adenocarcinoma cells in vitro, and exhibits antitumor efficacy in mouse xenograft models. Together, these findings establish dimer-interface cysteine targeting as a mechanism-based and therapeutically relevant strategy for modulating PHGDH function, and highlight the potential of CoDEL for discovering covalent inhibitors of protein-protein interfaces.
- 12 June 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (12) , 14530-14554
Discovery of a Covalent Inhibitor Targeting the PHGDH Dimer Interface with Antitumor Efficacy
Protein oligomerization is functionally essential for many enzymes, yet small-molecule strategies that directly target dimer interfaces remain challenging. Cysteine residues at protein dimer interfaces offer chemically addressable sites for modulating oligomeric assembly. Here, we used covalent DNA-encoded chemical library (CoDEL) screening to identify site-selective covalent hits targeting the PHGDH dimer interface. Covalent hits emerging from CoDEL screening were optimized to yield a selective covalent inhibitor engaging the interfacial Cys281. A representative compound, D5-2, potently disrupts PHGDH dimerization and inhibits its enzymatic activity, restores sensitivity to EGFR tyrosine kinase inhibitors in resistant lung adenocarcinoma cells in vitro, and exhibits antitumor efficacy in mouse xenograft models. Together, these findings establish dimer-interface cysteine targeting as a mechanism-based and therapeutically relevant strategy for modulating PHGDH function, and highlight the potential of CoDEL for discovering covalent inhibitors of protein-protein interfaces.
- Open Access
- 20 April 2026
- Published by Wiley in ChemMedChem
- Vol. 21 (8) , e202501032
DNA‐Encoded Libraries for the Discovery of E3 Ligase Ligands
DNA‐encoded library (DEL) technology has emerged as a powerful tool to accelerate drug discovery, and its application has expanded to challenging targets such as E3 ubiquitin ligases, whose ligands are essential for the development of targeted therapies, including proteolysis‐targeting chimeras (PROTACs). In this review, we summarize recent advances in the use of DELs for the discovery of small‐molecule non‐covalent E3 ligase ligands and discuss their advantages in hit‐to‐lead optimization and the design of targeted protein degradation systems. Furthermore, we highlight the potential and application basis of covalent DELs and DNA‐encoded cyclic peptide libraries, which together outline promising future directions for DEL‐based discovery of E3 ligase ligands. Emerging DEL‐based strategies for the direct discovery and optimization of TPD molecules are also discussed.
- 20 April 2026
- Published by Wiley in ChemMedChem
- Vol. 21 (8) , e202501032
Open AccessDNA‐Encoded Libraries for the Discovery of E3 Ligase Ligands
DNA‐encoded library (DEL) technology has emerged as a powerful tool to accelerate drug discovery, and its application has expanded to challenging targets such as E3 ubiquitin ligases, whose ligands are essential for the development of targeted therapies, including proteolysis‐targeting chimeras (PROTACs). In this review, we summarize recent advances in the use of DELs for the discovery of small‐molecule non‐covalent E3 ligase ligands and discuss their advantages in hit‐to‐lead optimization and the design of targeted protein degradation systems. Furthermore, we highlight the potential and application basis of covalent DELs and DNA‐encoded cyclic peptide libraries, which together outline promising future directions for DEL‐based discovery of E3 ligase ligands. Emerging DEL‐based strategies for the direct discovery and optimization of TPD molecules are also discussed.
- 3 March 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (5) , 5622-5647
Discovery of 1-(Azetidin-3-ylmethyl)-1 H -benzo[ d ]imidazole Derivatives as Efficient GSTP1 Inhibitors for Gastric Cancer Treatment via Warhead Removal Strategy
Gastric cancer is commonly diagnosed at advanced stages and frequently develops multidrug resistance (MDR). Clinical evidence highlights the overexpression of glutathione S-transferase pi 1 (GSTP1) in gastric cancer, which is closely associated with tumor progression and the development of MDR. However, highly potent and selective GSTP1 inhibitors remain scarce. Guided by our previously reported covalent DNA-encoded library (DEL) hit, a series of warhead-removed 1-(azetidin-3-ylmethyl)-1H-benzo[d]imidazole derivatives were obtained as noncovalent GSTP1 inhibitors. The most potent compound, 16n, inhibited GSTP1 enzymatic activity with an IC50 value of 0.79 ± 0.05 μM and demonstrated improved isoform selectivity. In human gastric cancer cells (AGS, HGC27, and NUGC-3), 16n dose-dependently suppressed proliferation and increased intracellular reactive oxygen species levels while decreasing glutathione levels. Importantly, 16n exhibited favorable systemic exposure and achieved 58% tumor growth inhibition with good tolerability in HGC27 xenograft mouse models. Collectively, 16n represents a promising noncovalent GSTP1 inhibitor for the treatment of gastric cancer.
- 3 March 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (5) , 5622-5647
Discovery of 1-(Azetidin-3-ylmethyl)-1 H -benzo[ d ]imidazole Derivatives as Efficient GSTP1 Inhibitors for Gastric Cancer Treatment via Warhead Removal Strategy
Gastric cancer is commonly diagnosed at advanced stages and frequently develops multidrug resistance (MDR). Clinical evidence highlights the overexpression of glutathione S-transferase pi 1 (GSTP1) in gastric cancer, which is closely associated with tumor progression and the development of MDR. However, highly potent and selective GSTP1 inhibitors remain scarce. Guided by our previously reported covalent DNA-encoded library (DEL) hit, a series of warhead-removed 1-(azetidin-3-ylmethyl)-1H-benzo[d]imidazole derivatives were obtained as noncovalent GSTP1 inhibitors. The most potent compound, 16n, inhibited GSTP1 enzymatic activity with an IC50 value of 0.79 ± 0.05 μM and demonstrated improved isoform selectivity. In human gastric cancer cells (AGS, HGC27, and NUGC-3), 16n dose-dependently suppressed proliferation and increased intracellular reactive oxygen species levels while decreasing glutathione levels. Importantly, 16n exhibited favorable systemic exposure and achieved 58% tumor growth inhibition with good tolerability in HGC27 xenograft mouse models. Collectively, 16n represents a promising noncovalent GSTP1 inhibitor for the treatment of gastric cancer.
- Top Cited PapersOpen Access
- 13 February 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (7) , eaea9832
Structure-based design of an opioid receptor modulator for enhanced morphine analgesia
The alarming rates of deaths due to opioid overdose present an urgent need for safer opioid analgesics. Positive allosteric modulators (PAMs) of opioid receptors (ORs) offer a promising approach to enhance opioid efficacy while reducing risks of overdose. In this study, we unveil the selective mechanism of PAM modulation of the OR family through structure elucidation of the δ-opioid receptor and μ-opioid receptor (μOR) bound to orthosteric agonists and PAMs BMS986187 (BMS187) and BMS986122 (BMS122). In addition, we uncovered an unexpected but conserved allosteric site across the transmembrane helices TM2 to TM4 of ORs, occupied by BMS187 but not BMS122. Leveraging these structural insights, we designed 9-(5-(4-chlorophenyl)furan-2-yl)-3,3,6,6-tetramethyl-3,4,5,6,7,9-hexahydro-1 H -xanthene-1,8(2 H )-dione (MPAM-15), whose αβ cooperativity factor is 33-fold higher than BMS122 and threefold higher than BMS187, indicating markedly stronger positive allosterism. Animal studies demonstrate that MPAM-15 shows excellent brain penetration and enhances morphine-induced antinociception without exacerbating respiratory depression or constipation. Molecular dynamics simulations revealed that MPAM-15 promotes and stabilizes the conformational equilibrium of μOR toward the canonical active state, providing a mechanistic basis for its enhanced allosteric potency. These discoveries substantially advance our understanding of OR allosteric mechanism and pave the way for the structure-based development of allosteric opioid analgesics.
- 13 February 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (7) , eaea9832
Top Cited PapersOpen AccessStructure-based design of an opioid receptor modulator for enhanced morphine analgesia
The alarming rates of deaths due to opioid overdose present an urgent need for safer opioid analgesics. Positive allosteric modulators (PAMs) of opioid receptors (ORs) offer a promising approach to enhance opioid efficacy while reducing risks of overdose. In this study, we unveil the selective mechanism of PAM modulation of the OR family through structure elucidation of the δ-opioid receptor and μ-opioid receptor (μOR) bound to orthosteric agonists and PAMs BMS986187 (BMS187) and BMS986122 (BMS122). In addition, we uncovered an unexpected but conserved allosteric site across the transmembrane helices TM2 to TM4 of ORs, occupied by BMS187 but not BMS122. Leveraging these structural insights, we designed 9-(5-(4-chlorophenyl)furan-2-yl)-3,3,6,6-tetramethyl-3,4,5,6,7,9-hexahydro-1 H -xanthene-1,8(2 H )-dione (MPAM-15), whose αβ cooperativity factor is 33-fold higher than BMS122 and threefold higher than BMS187, indicating markedly stronger positive allosterism. Animal studies demonstrate that MPAM-15 shows excellent brain penetration and enhances morphine-induced antinociception without exacerbating respiratory depression or constipation. Molecular dynamics simulations revealed that MPAM-15 promotes and stabilizes the conformational equilibrium of μOR toward the canonical active state, providing a mechanistic basis for its enhanced allosteric potency. These discoveries substantially advance our understanding of OR allosteric mechanism and pave the way for the structure-based development of allosteric opioid analgesics.
- Open Access
- 23 January 2026
- Published by American Chemical Society (ACS) in JACS Au
- Vol. 6 (2) , 1370-1381
Fusion Strategy of DNA-Encoded Libraries Drives Discovery of Allosteric Inhibitors of SARS-CoV-2 RdRp
Allosteric regulation is a central mechanism for modulating biological functions and offers an attractive strategy in drug discovery, particularly for targets considered challenging or “undruggable.” However, the discovery of allosteric inhibitors is hindered by poorly defined binding sites and the lack of effective screening approaches. Here, we present a dual DNA-encoded library (DEL) screening strategy that integrates reversible DEL and covalent DEL (CoDEL) technologies to identify novel allosteric inhibitors of the SARS-CoV-2 RNA-dependent RNA polymerase (RdRp). Using this approach, we discovered the first covalent allosteric inhibitors of RdRp, which engage a previously uncharacterized pocket on the nsp8 subunit and form a covalent bond with Cys114. Subsequent SAR studies and biochemical assays confirmed the allosteric mechanism and elucidated structural determinants of activity. This work highlights the power of integrating reversible DEL screening with CoDEL screening for ligand discovery and establishes a generalizable strategy to identify covalent allosteric modulators for therapeutically important targets for therapy or active probe design.
- 23 January 2026
- Published by American Chemical Society (ACS) in JACS Au
- Vol. 6 (2) , 1370-1381
Open AccessFusion Strategy of DNA-Encoded Libraries Drives Discovery of Allosteric Inhibitors of SARS-CoV-2 RdRp
Allosteric regulation is a central mechanism for modulating biological functions and offers an attractive strategy in drug discovery, particularly for targets considered challenging or “undruggable.” However, the discovery of allosteric inhibitors is hindered by poorly defined binding sites and the lack of effective screening approaches. Here, we present a dual DNA-encoded library (DEL) screening strategy that integrates reversible DEL and covalent DEL (CoDEL) technologies to identify novel allosteric inhibitors of the SARS-CoV-2 RNA-dependent RNA polymerase (RdRp). Using this approach, we discovered the first covalent allosteric inhibitors of RdRp, which engage a previously uncharacterized pocket on the nsp8 subunit and form a covalent bond with Cys114. Subsequent SAR studies and biochemical assays confirmed the allosteric mechanism and elucidated structural determinants of activity. This work highlights the power of integrating reversible DEL screening with CoDEL screening for ligand discovery and establishes a generalizable strategy to identify covalent allosteric modulators for therapeutically important targets for therapy or active probe design.
- Open Access
- 20 November 2025
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 147 (48) , 44396-44405
Biocatalytic- and Chemoproteomic-Guided Discovery of a PHGDH Inhibitor from Chemoenzymatic-Promoted DNA-Encoded Libraries Selection Platform
DNA-encoded libraries (DELs) have emerged as an effective and efficient selection strategy for lead compound discovery in academia and industry over the past few decades. Despite recent advancements in this field, DEL remains limited by sensitive DNA-based constructs, particularly with low selection success rates resulting from the random selection of targets. Here, we describe a chemoenzymatic on-DNA reaction for DEL syntheses and develop a chemoproteomic-guided DEL selection platform. This platform, termed FF tags-biocatDEL, integrates DEL technology, chemoenzymatic synthesis, and fully functionalized (FF) chemical tags to match DELs with selection targets, even with limited information about ligandable hotspots. Using two diazirine-based FF indole probes, we comprehensively surveyed binding partners in cells and identified phosphoglycerate dehydrogenase (PHGDH) as a potential target for DEL selection. DEL01 and DEL02 were designed, synthesized, and selected against PHGDH, leading to the identification of a novel enzyme-active compound with an IC50 value of 2.5 μM. Our strategy, utilizing FF tags-biocatDEL, establishes a generalizable workflow for rapid target hunting and ligand discovery. It provides an effective method for precisely matching DELs with potential targets, demonstrating its significant potential as a complementary approach to drug discovery based on DELs.
- 20 November 2025
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 147 (48) , 44396-44405
Open AccessBiocatalytic- and Chemoproteomic-Guided Discovery of a PHGDH Inhibitor from Chemoenzymatic-Promoted DNA-Encoded Libraries Selection Platform
DNA-encoded libraries (DELs) have emerged as an effective and efficient selection strategy for lead compound discovery in academia and industry over the past few decades. Despite recent advancements in this field, DEL remains limited by sensitive DNA-based constructs, particularly with low selection success rates resulting from the random selection of targets. Here, we describe a chemoenzymatic on-DNA reaction for DEL syntheses and develop a chemoproteomic-guided DEL selection platform. This platform, termed FF tags-biocatDEL, integrates DEL technology, chemoenzymatic synthesis, and fully functionalized (FF) chemical tags to match DELs with selection targets, even with limited information about ligandable hotspots. Using two diazirine-based FF indole probes, we comprehensively surveyed binding partners in cells and identified phosphoglycerate dehydrogenase (PHGDH) as a potential target for DEL selection. DEL01 and DEL02 were designed, synthesized, and selected against PHGDH, leading to the identification of a novel enzyme-active compound with an IC50 value of 2.5 μM. Our strategy, utilizing FF tags-biocatDEL, establishes a generalizable workflow for rapid target hunting and ligand discovery. It provides an effective method for precisely matching DELs with potential targets, demonstrating its significant potential as a complementary approach to drug discovery based on DELs.
- 1 October 2025
- Published by Elsevier in Current Opinion in Structural Biology
- Vol. 95, 103163
Recent advances in DNA-encoded libraries: From covalent targeting to protein profiling
- 1 October 2025
- Published by Elsevier in Current Opinion in Structural Biology
- Vol. 95, 103163
Recent advances in DNA-encoded libraries: From covalent targeting to protein profiling
- 22 August 2025
- Published by American Chemical Society (ACS) in Organic Letters
- Vol. 27 (35) , 9771-9776
On-DNA Synthesis of Privileged Dihydropteridinones via Diboron-Mediated Cyclizations
DNA-encoded chemical library (DECL) technology has emerged as a pivotal platform for high-throughput screening in drug discovery. Expanding the chemical space of DECLs requires the development of novel, robust, and DNA-compatible transformations, with atom-economical cyclizations being particularly attractive for generating drug-like scaffolds. The 7,8-dihydropteridinone core represents a pharmacologically important heterocycle whose incorporation into DECLs has been hampered by harsh synthetic conditions. Herein, we report two distinct diboron-mediated catalytic strategies that enable efficient on-DNA synthesis of diverse 7,8-dihydro-6(5H)-pteridinone derivatives. Both methods proceed under mild, aqueous-compatible conditions and afford high conversions, providing a powerful solution for accessing this privileged scaffold.
- 22 August 2025
- Published by American Chemical Society (ACS) in Organic Letters
- Vol. 27 (35) , 9771-9776
On-DNA Synthesis of Privileged Dihydropteridinones via Diboron-Mediated Cyclizations
DNA-encoded chemical library (DECL) technology has emerged as a pivotal platform for high-throughput screening in drug discovery. Expanding the chemical space of DECLs requires the development of novel, robust, and DNA-compatible transformations, with atom-economical cyclizations being particularly attractive for generating drug-like scaffolds. The 7,8-dihydropteridinone core represents a pharmacologically important heterocycle whose incorporation into DECLs has been hampered by harsh synthetic conditions. Herein, we report two distinct diboron-mediated catalytic strategies that enable efficient on-DNA synthesis of diverse 7,8-dihydro-6(5H)-pteridinone derivatives. Both methods proceed under mild, aqueous-compatible conditions and afford high conversions, providing a powerful solution for accessing this privileged scaffold.
- Open Access
- 5 August 2025
- Published by American Chemical Society (ACS) in ChemRxiv
FF tags-SynbioDEL: Biosynthetic and Proteome Profiling-Guided Discovery of PHGDH Inhibitor from Reversible DNA-Encoded Libraries Selection Platform
DNA-encoded libraries (DELs) have emerged as an effective and efficient selection strategy for lead compound discovery in academia and industry over the past decades. Despite recent advancements in this field, DEL is still limited by sensitive DNA-based constructs, especially low selection success rates from random selection of targets. Here, we describe a biosynthesis on-DNA reaction for DEL syntheses and develop a proteome profiling-guided reversible DEL selection platform. This platform, termed FF tags-SynbioDEL, integrates DEL technology, biocatalysis, and fully-functionalized (FF) chemical tags to match DELs with selection targets, even with limited information on ligandable hotspots. Using a diazirine-based FF indole probe, we comprehensively surveyed binding partners in live cells and identified phosphoglycerate dehydrogenase (PHGDH) as a potential target for DEL selection. DEL01 and DEL02 were designed, synthesized, and selected against PHGDH, leading to the identification of a novel enzyme-active compound with an IC50 value of 2.4 μM. Our strategy, utilizing FF tags-SynbioDEL, establishes a generalizable workflow for rapid target hunting, ligand discovery, and optimization. This approach provides a transformative method for matching DELs with potential targets, demonstrating its significant potential in drug discovery.
- 5 August 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessFF tags-SynbioDEL: Biosynthetic and Proteome Profiling-Guided Discovery of PHGDH Inhibitor from Reversible DNA-Encoded Libraries Selection Platform
DNA-encoded libraries (DELs) have emerged as an effective and efficient selection strategy for lead compound discovery in academia and industry over the past decades. Despite recent advancements in this field, DEL is still limited by sensitive DNA-based constructs, especially low selection success rates from random selection of targets. Here, we describe a biosynthesis on-DNA reaction for DEL syntheses and develop a proteome profiling-guided reversible DEL selection platform. This platform, termed FF tags-SynbioDEL, integrates DEL technology, biocatalysis, and fully-functionalized (FF) chemical tags to match DELs with selection targets, even with limited information on ligandable hotspots. Using a diazirine-based FF indole probe, we comprehensively surveyed binding partners in live cells and identified phosphoglycerate dehydrogenase (PHGDH) as a potential target for DEL selection. DEL01 and DEL02 were designed, synthesized, and selected against PHGDH, leading to the identification of a novel enzyme-active compound with an IC50 value of 2.4 μM. Our strategy, utilizing FF tags-SynbioDEL, establishes a generalizable workflow for rapid target hunting, ligand discovery, and optimization. This approach provides a transformative method for matching DELs with potential targets, demonstrating its significant potential in drug discovery.